DUBLIN--(BUSINESS WIRE)--The "Osteogenesis Imperfecta - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
Osteogenesis Imperfecta - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Osteogenesis Imperfecta (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Osteogenesis Imperfecta (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteogenesis Imperfecta and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 2 and 1 respectively.
Osteogenesis Imperfecta (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Companies Featured
- Amgen Inc.
- Bone Therapeutics SA
- Genzyme Corp.
- Mereo Biopharma Group plc
- Mesentech Inc.
- SOM Biotech SL
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/z3s7cf/osteogenesis?w=4
